Introduction
When Yohei Ito was born in 1923 tumor virology was well on its path. Warts had been transmitted by cell-free extracts, Ellermann and Bang had shown in Copenhagen the viral nature of chicken leukemias, and most importantly, Peyton Rous in 1911 had demonstrated that chicken sarcomas, the first solid tumor if we ignore the warts, were transmissible by cellfree extracts.
Yohei During his stay in Seattle, in Dr Evans laboratory, he became familiar with the Shope papillomavirus system, inducing mostly papillomas in its natural host, the cottontail rabbit, but rapidly progressing papillomas converting into squamous cell carcinomas in domestic rabbits. The successful transmission of tobacco mosaic disease by phenol extracts stimulated him to similar experiments with papillomatous tissue and subsequently with similarly treated partially purified virus preparations. The key papers appeared in 1960 and 1961, [1] [2] [3] in three of them Yohei Ito as sole author, a fourth one under the co-authorship with Evans. 4 The first one of this series demonstrated the induction of tumors by phenol extracts from papillomatous tissue of cottontail rabbits, the one with Evans included such extracts from partially purified virus preparations.
This was a major breakthrough in tumor virology. It demonstrated for the first time the tumorigenic potential of specific nucleic acids and showed simultaneously that viral DNA could act as a solitary carcinogen. The real appreciation of these data came only much later (about 20 years later) with the advent of human papillomavirus studies in the early 1980s.
Since then, Ito kept a keen interest in papillomavirus research and contributed a number of important studies to the Shope papillomavirus system. He did not however restrict his activities to this virus group. In 1966, he identified a rabbit Professor Yohei Ito, 1923 Ito, -1985 (the photograph is courtesy of Professor Yoshiaki Ito). kidney vacuolating virus, 5 and was one of the earliest experimentors in immortalization of human lymphocytes by leukemic extracts, 6 without recognizing at that time the contribution of Epstein-Barr virus to this event. Subsequently he started a large series of studies on EBV in lymphoblasts and EBV seroepidemiology. Jointly with Hirayama, 7 he prompted an exciting hypothesis on nasopharyngeal cancer development as the consequence of tumor promoter induction and was co-author on a very important paper establishing a cervical carcinoma cell line (SiHa), now used in many laboratories. 8 From the early 1970s he moved more and more into retrovirus research, starting with the observation of intracisternal A-and C-type particles in pulmonary tumors of mice, 9 the kinetics of leukemogenesis by Rauscher leukemia virus to studies in human cells. This was later further stimulated by his collaboration with Bob Gallo's group on human T cell leukemia virus. Here again he was instrumental in providing numerous new data.
In spite of his increasing number of national and international activities and an expansive research program he never lost his interest in papillomavirus research. This is particularly documented by his organization of the 1984 Conference on Papillomaviruses which was for all participants an unforgettable event.
Yohei Ito was a brilliant and very critical scientist and for all of those who had the privilege to know him well, a warm human being and friend. His contributions will keep a special place in the history of tumor virology and most notably in papillomavirus research.
What happened after the discoveries of Ito in this field, what are the present perspectives of papillomavirus research?
A few historical aspects
In the 1970s, the papillomavirus field started to move rapidly. This was in part the consequence of technical developments, the availability of restriction endonucleases, of novel hybridization procedures and of cloning techniques, in part it was also the development of new ideas on a possible role of members of this virus group in human malignant disease. Even prior to this period, the physical properties of papillomavirus particles and the structure of its DNA had been resolved. 10 First reports on the plurality of HPV types appeared in 1976 11 and in 1977. 12, 13 It was of particular interest that specific HPV types (HPV5) could be discovered in malignant skin tumors of patients with a rare hereditary condition, Epidermodysplasia verruciformis.
14 It was not however before the early 1980s that the papillomavirus field virtually 'exploded'. This resulted from the isolation of specific novel HPV types from genital warts, 15, 16 and shortly thereafter also from biopsies of cancer of the cervix. 17, 18 The regular presence of these HPV types (particularly HPV16 and HPV18) in cancers of the cervix resulted in a rapid increase in interest in this virus group and in the isolation of many additional HPV genotypes.
Role of HPVs in human cancer
Reports on a possible role of HPV in anogenital cancers, specifically in cancer of the cervix appeared between 1974 and 1976. [19] [20] [21] They were based however on theoretical considerations and at this period not experimentally substantiated. The demonstration of novel HPV types by the same group in the 1980s in cervical cancer, soon followed by similar reports in premalignant cervical and vulvar lesions, in penile and vulvar cancers, provided a new perspective. In 1985, it had been shown that HPV commonly integrates into host cell DNA in the course of cervical carcinogenesis, frequently accompanied by the development of deletions involving a specific viral region (partially E2 and partially L2), and that two genes of the HPV genome (E6 and E7) were uniformly active in the tumor cells. 22 During the 1980s, a number of other important properties of HPV types found in cervical cancer (now labeled 'high risk' HPV) became apparent: they were able to immortalize a broad spectrum of different human cell types (reviewed in Ref. 23 ). After prolonged cultivation some of these immortalized cell cultures spontaneously converted to malignant growth. 24, 25 This revealed the potential of such high risk types to act as 'solitary carcinogens'. 26, 27 Interesting new perspectives came up from observations demonstrating -similar to other DNA tumor virus systems (SV40, oncogenic adenoviruses) -the binding of the cellular proteins p53 to the viral oncoprotein E6 and of pRb to E7. 28, 29 The E6/p53 interaction resulted in a rapid degradation of p53, obviously disturbing an important regulatory role of this protein in DNA repair and transcriptional regulation. Similarly, the E7/pRb interaction resulted in phosphorylation of pRB, its release from complexes with the transcription factor E2F and, as a consequence, to mitotic activation. Although these studies suggested initially a straightforward interpretation of growth stimulatory activity by these viruses, subsequent analyses revealed much more complex modes of action in immortalization and malignant conversion of HPV-infected cells.
In addition to a large number of experimental studies, epidemiological and seroepidemiological studies stressed the etiological role of specific HPV types in cancer of the cervix, but also in a high percentage of other anogenital cancers (cancer of the anus, vulva, penis and vagina). Therefore, a consensus conference of the International Agency of Research on Cancer in Lyon concluded in 1995 that 'HPV16 and HPV18 are carcinogenic to humans'.
30
Major areas of present study
Identification of more HPV types
Within the past 15 years the human papillomavirus group developed into the most complex group of infectious human pathogens. Although different histologies of human warts were considered for decades as Standortvarianten, as modifications due to the infection of different types of cells, nobody could assume the enormous heterogeneity of the HPV group as it emerges today. At present, 82 different genotypes have been fully cloned and sequenced. The differences between individual genotypes amount to at least 10% changes in nucleotides within the most conserved region of the genome, the L1 open reading frame, coding for the major structural protein. In addition, polymerase chain reaction analysis with degenerate consensus primers and subsequent sequencing of amplified parts of the L1 region suggests the existence of at least 70 additional genotypes, pointing to a puzzling multitude of HPV genotypes.
It is clearly of importance to analyze these putative novel types further. Many of them have been revealed in warts of organ transplant recipients, but also in non-immunosuppressed individuals. Interestingly some of these types also originate from squamous and basal cell carcinomas of the skin. These tumors have recently regularly been shown to contain the DNA of HPV types. [31] [32] [33] [34] Besides cancers of the skin, approximately 20% of cancers of the oral cavity, tongue, and to a slightly lesser degree, the larynx have been shown to contain mainly anogenital HPV types. Since the mode of viral DNA persistence as well as the pattern of E6/E7 oncogene expression corresponds to observations made in cancer of the cervix biopsies, it appears to be likely that these tumors are also caused by such HPV infections. Similar to cancers of the oropharynx, close to 15% of esophageal cancers have recently been found to contain in part novel HPV types. The role of these virus infections in the induction of esophageal cancer remains to be established. The linkage of specific HPV types to some human cancers points, however, to the importance of HPV-type identification. Given the speed of new type characterizations during the past few years it is likely that many more novel HPV types will appear S5 in the future. An explanation for this enormous heterogeneity of this virus group is still missing, their mutation rate does not appear to be exceptionally high.
It is probably justified to state that presently close to 15% of the global cancer incidence in females is due to papillomavirus infections, whereas in males it barely reaches 5%.
Interaction with cellular proteins
Our understanding of HPV pathogenicity and tumorigenicity will depend to a substantial degree on interactions of viral oncoproteins with components of the normal cell. It became quite clear in recent years that both oncoproteins (E6 and E7) exert pleiotropic effects. 35 Besides their interaction with p53 and pRb a number of additional interactions with cellular proteins have been revealed in recent years, adding to the complexity of HPV-caused tumorigenesis. A functional interference has been demonstrated with the cyclin-dependent kinase inhibitors p16 INK4 , p21
CIP1 and p27 KIP1 apparently blocking their negative regulation of the cell cycle. More recently, an interaction of E7 with the M2 pyruvate kinase was demonstrated. This may have important implications for the glucose metabolism of the HPV-carrying cell.
Modification of the expression pattern of cellular genes is frequently mediated by E6 or E7 oncoproteins. This may in part be due to the release of the transcription factor E2F, but is probably also caused by other types of interaction. Among the genes modified in their activity are cyclins E and A, Bmyb, telomerase, c-fos and c-jun. In all these instances, viral oncoprotein expression activates the expression of these cellular proteins. Smooth muscle ␣-actin, on the other hand, becomes suppressed. It is very likely that a number of additional genes will be identifed in the future whose genetic activity is either activated or suppressed by the function of the HPV oncoproteins. Obviously, these proteins function as a pleiotropic switch, interacting with a multitude of cellular promoters.
Regulation of viral transcription
Specific patterns of tumor development in humans are difficult to understand if we do not assume a cellular regulation of viral oncogene transcription or function. These include the latency periods between primary infection and tumor development which regularly cover several decades. 36 In addition, tumor monoclonality, the small number of infected individuals eventually developing the respective form of cancer and interactions with chemical and physical carcinogens (see below), all seem to point to some kind of cellular control of viral oncoproteins, interrupted in the rare case of tumor development.
Such considerations led to the cellular interference factor (CIF) concept, initially assuming at least one cellular factor which needs to be knocked out in tumor progression. 37 In subsequent years, it became obvious that there exist at least two signaling cascades engaged in the regulation of HPV transcription and viral oncoprotein function, the CIF factor consequently was replaced by the CIF concept. 26 Whereas functional control can be deduced from somatic cell hybridization studies, revealing complementation of HPVimmortalized clones for senescence in spite of continuing viral oncogene expression, transcriptional control can be neatly demonstrated by inoculating HPV-immortalized cells into suitable animal hosts (nude mice). Under these conditions HPV transcription is drastically reduced within a 3-day period. The transcriptional suppression can be achieved in tissue culture by adding human macrophages to the immortalized cells. Similarly, a cytokine excreted by macrophages, TNF-␣, mediates the same effect. 38 A careful analysis of the underlying mechanism suggests that TNF-␣ triggers a signaling cascade which modifies the AP-1 transcription factor. Whereas under in vitro (tissue culture) conditions this complex consists of c-jun/c-jun homodimers or of c-jun/c-fos heterodimers, TNF-␣ addition results in a specific phosphorylation of c-jun and its heterodimerization with fra-I. Apparently c-jun/fra-I heterodimers block the activity of the HPV promoter.
In malignant cells the same signaling cascade is inactive, apparently due to mutational interruptions somewhere within this pathway. At this stage malignant progression emerges as the consequence of the interruption of two independent regulatory pathways: an intracellular pathway interfering with the function of viral oncoproteins, and an intercellular pathway, blocking viral oncogene transcription in cells which are still able to proliferate. The identification of cellular genes regulating these pathways will be an important question for the future.
Interaction with other carcinogens
During the 1930s, Peyton Rous and his associates 39, 40 noted that tarring of the rabbit skin or, as performed in later experiments, exposure to chemical carcinogens, enhanced the effect of cottontail rabbit papillomavirus (CRPV) infections substantially. Virus-positive tumors emerged earlier and at higher frequency and converted more rapidly to malignant growth. These experiments also formed to some extent the background for Yohei Ito's studies about 25 years later.
In subsequent years additional interactions of papillomavirus infections with chemical or physical carcinogens have been described, some of them also in humans. They include a Mastomys natalensis papillomavirus, a papillomavirus from Syrian hamsters, as well as a number of human papillomavirus types. It is tempting to speculate that this interaction results from modifications in host cell genes naturally engaged in the control of the respective papillomavirus infections.
A fascinating new field of studies results from the demonstration of in part novel HPV types in non-melanoma skin cancers. The vast majority of these tumors develop on sunlightexposed parts of the skin. Interestingly, the majority of papillomas in immunosuppressed patients also originate at these sites. Some of them also convert into malignant tumors after prolonged periods of time. The presence of UV-responsive elements in the viral promoter region of many of these agents permits the suspicion that HPV/UV-light interaction may represent a major factor in skin carcinogenesis.
Preventive vaccination
The identification of specific HPV types as human carcinogens, as well as the high global incidence of cervical cancer (11.8% of all cancers among females) prompted efforts to develop suitable vaccines in order to prevent these infections if possible. At this stage the data look very promising: by using genetically engineered viral capsid, spontaneously assembled L1 or L1 and L2 proteins, such preparations proved to be remarkably successful in animal experiments. Dogs could be completely protected against the development of oral and lin-gual warts, caused by the dog oral papillomavirus. Similarly, a high degree of protection was achieved in rabbits by analogous preparations of CRPV. Here the vaccine prevented the development of malignant tumors, thus revealing an anticancer potential.
For vaccination in humans, similar virus-like particles have been produced for HPV6, 11, 16 and 18 and are presently being evaluated in phase I clinical studies. It is anticipated that phase II studies will be initiated in the near future. Therefore there exists the promise of a true specific anti-cancer vaccine which in addition to hepatitis B vaccines will have the potential to prevent a significant proportion of common human cancers.
Therapeutic vaccination
Based on similar considerations, antigenic epitopes of E6 and even more so of E7 proteins are presently being developed, either as polypeptide vaccines, as chimeric proteins integrated into L1 proteins or as DNA vaccines, in order to immunize the host in case of pre-existing infections. The technical developments in this direction are well advanced and a first phase I trial has been published already.
It is difficult now to predict the effectiveness of this latter approach. It appears that many of the carcinoma carriers, inspite of abundant E7 oncoprotein expression, fail to recognize this protein in carcinoma cells. This may represent a problem of proper antigen presentation and clearly requires further investigation.
The production and application of chimeric proteins with preventive and immunotherapeutic potential emerges as the most interesting development. The theoretical potential of such vaccines is substantial. A significant reduction in cancer incidence could be an important consequence in case their application turns out to be effective.
Chemotherapy
Chemotherapy of papillomavirus infections is still at a very early stage. In preclinical experimentation some drugs are able to suppress HPV gene activity. Retinoic acid is one of these substances. Pyrrolidine-di-thiocarbamate is also remarkably effective in suppressing HPV gene activity selectively in immortalized cells. Deoxyglucose turns out to be a transcriptional repressor for HPV in immortalized, as well as in malignant cells when tested under tissue culture conditions.
A number of cytokines have been described affecting HPV transcription: these involve TNF-␣, TGF-␤, some interleukins, and leukoregulin. To my knowledge, none have as yet been applied under clinical conditions. It is however of interest to note that constitutive expression of a chemokine, the macrophage-chemoattractant protein 1 (MCP-1) in cervical carcinoma cells suppressed tumorigenicity in the nude mouse system to some extent, but in no case completely. It will be interesting to assess the clinical effect of MCP-1 administration, possibly after gene therapeutic application.
Conclusions
Papillomavirus research progressed rapidly in recent years. The identification of cancer-causing types in humans and a partial understanding of their mechanism of action resulted in their acceptance as human carcinogens. Of course, a large number of questions remain unanswered. The puzzling plurality of HPV types, their role in non-genital malignancies, their interaction with chemical and physical factors, their replicative restriction to differentiated cells, these and many other questions remain presently unanswered.
Yohei Ito was one of the great pioneers in this field and made very important early contributions. We owe him much gratitude.
